BSI-022-B

N/A

Report date: 2023/05/22 10:16:05

Base Information

Drug NameBSI-022-B
Drug Alias NameBSI-022-B
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsSolid tumoursMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiosion Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiosion Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A